B. Metzler seel. Sohn & Co. AG Has $5.05 Million Stock Position in Bristol Myers Squibb Company $BMY

B. Metzler seel. Sohn & Co. AG reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 28.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 111,979 shares of the biopharmaceutical company’s stock after selling 44,554 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in Bristol Myers Squibb were worth $5,050,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Brighton Jones LLC increased its position in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the period. Sivia Capital Partners LLC grew its position in Bristol Myers Squibb by 59.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 2,786 shares during the last quarter. United Bank grew its position in Bristol Myers Squibb by 15.0% in the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after purchasing an additional 3,277 shares during the last quarter. Wedbush Securities Inc. increased its holdings in shares of Bristol Myers Squibb by 2.4% during the 2nd quarter. Wedbush Securities Inc. now owns 56,957 shares of the biopharmaceutical company’s stock worth $2,637,000 after purchasing an additional 1,353 shares during the period. Finally, AE Wealth Management LLC raised its position in shares of Bristol Myers Squibb by 271.1% during the second quarter. AE Wealth Management LLC now owns 253,305 shares of the biopharmaceutical company’s stock valued at $11,725,000 after buying an additional 185,045 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: U.S. FDA approved Sotyktu (deucravacitinib) for adults with active psoriatic arthritis — a label expansion that can broaden Sotyktu’s market opportunity and revenue runway. U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
• Positive Sentiment: BMY declared a quarterly dividend of $0.63/share (ex-dividend April 2), maintaining a high-yield payout that supports income-focused investors and can underpin the stock’s valuation. Dividend Announcement
• Positive Sentiment: Reblozyl showed positive Phase 2 results in alpha-thalassemia and has exceeded $2.3B in annualized sales — evidence Reblozyl is becoming a material growth driver as older drugs decline. Reblozyl Phase 2 Success Shapes Bristol Myers Squibb Valuation Story
• Neutral Sentiment: Bristol-Myers Squibb is tracking the real-world impact of KarXT in schizophrenia — useful clinical/market data but longer-term and unlikely to move near-term earnings. Bristol-Myers Squibb Tracks Real-World Impact of KarXT in Schizophrenia
• Negative Sentiment: Q4 results showed revenue roughly in line but EPS missed consensus (reported $1.26 vs. ~$1.65 expected), which prompted investor selling and weighed on the stock. Earnings and Market Reaction
• Negative Sentiment: Recent articles highlight a larger-than-market intraday decline and analyst focus on legacy-product pressures — shorter-term sentiment and volatility remain a risk until new product growth scales. Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Guggenheim reiterated a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Morgan Stanley reiterated an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Citigroup lifted their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a report on Friday, February 6th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Nine research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $61.00.

Bristol Myers Squibb Stock Down 0.9%

Shares of NYSE:BMY opened at $60.21 on Monday. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The firm has a market cap of $122.62 billion, a P/E ratio of 17.45, a P/E/G ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $63.33. The company’s 50-day moving average price is $57.66 and its two-hundred day moving average price is $51.03.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same period in the prior year, the firm posted $1.67 earnings per share. The company’s revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.2%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.